Ind-Swift Laboratories Limited Total Liabilities
Ind-Swift Laboratories Limited total liabilities. Based on the latest financial reports, Ind-Swift Laboratories Limited (INDSWFTLAB) has total liabilities worth Rs2.37 Billion INR (≈ $25.63 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Ind-Swift Laboratories Limited liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Ind-Swift Laboratories Limited (2006–2025)
Total liabilities of Ind-Swift Laboratories Limited from 2006 to 2025. This chart illustrates how Ind-Swift Laboratories Limited's total liabilities have evolved over time, based on quarterly financial data. Explore Ind-Swift Laboratories Limited long-term investment allocation to see how much of total assets are deployed in long-term investments.
Ind-Swift Laboratories Limited Competitors by Total Liabilities
The table below lists competitors of Ind-Swift Laboratories Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Five Point Holdings LLC
NYSE:FPH
|
USA | $814.88 Million |
|
Xiamen Goldenhome Co Ltd
SHG:603180
|
China | CN¥3.05 Billion |
|
Refex Industries Limited
NSE:REFEX
|
India | Rs-15.09 Billion |
|
Jiangsu Chunlan Refrigerating Equipment Stock Co Ltd
SHG:600854
|
China | CN¥165.69 Million |
|
Norske Skog Asa
OL:NSKOG
|
Norway | Nkr8.29 Billion |
|
Digiworld Corp
VN:DGW
|
Vietnam | ₫8.78 Trillion |
|
Hangzhou Coco Healthcare Products Co.Ltd.
SHE:301009
|
China | CN¥739.23 Million |
|
Beijing Sanfo Outdoor Products Co Ltd
SHE:002780
|
China | CN¥471.58 Million |
Liability Composition Analysis (2006–2025)
This chart breaks down Ind-Swift Laboratories Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Ind-Swift Laboratories Limited balance sheet assets.
Liquidity & Leverage Metrics
Ind-Swift Laboratories Limited Total Liabilities Ratios Explained
Ind-Swift Laboratories Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 1.91 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ind-Swift Laboratories Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ind-Swift Laboratories Limited (2006–2025)
The table below shows the annual total liabilities of Ind-Swift Laboratories Limited from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs2.65 Billion ≈ $28.70 Million |
-59.07% |
| 2024-03-31 | Rs6.48 Billion ≈ $70.12 Million |
-43.23% |
| 2023-03-31 | Rs11.42 Billion ≈ $123.52 Million |
-4.82% |
| 2022-03-31 | Rs12.00 Billion ≈ $129.77 Million |
-1.24% |
| 2021-03-31 | Rs12.15 Billion ≈ $131.40 Million |
-1.17% |
| 2020-03-31 | Rs12.29 Billion ≈ $132.95 Million |
-7.99% |
| 2019-03-31 | Rs13.36 Billion ≈ $144.50 Million |
-9.09% |
| 2018-03-31 | Rs14.70 Billion ≈ $158.95 Million |
-8.49% |
| 2017-03-31 | Rs16.06 Billion ≈ $173.70 Million |
-5.62% |
| 2016-03-31 | Rs17.02 Billion ≈ $184.04 Million |
+3.18% |
| 2015-03-31 | Rs16.49 Billion ≈ $178.36 Million |
+3.44% |
| 2014-03-31 | Rs15.94 Billion ≈ $172.43 Million |
+4.85% |
| 2013-03-31 | Rs15.21 Billion ≈ $164.45 Million |
+9.12% |
| 2012-03-31 | Rs13.94 Billion ≈ $150.71 Million |
+20.64% |
| 2011-03-31 | Rs11.55 Billion ≈ $124.92 Million |
+39.84% |
| 2010-03-31 | Rs8.26 Billion ≈ $89.33 Million |
+38.36% |
| 2009-03-31 | Rs5.97 Billion ≈ $64.56 Million |
+26.40% |
| 2008-03-31 | Rs4.72 Billion ≈ $51.08 Million |
+22.27% |
| 2007-03-31 | Rs3.86 Billion ≈ $41.78 Million |
+20.02% |
| 2006-03-31 | Rs3.22 Billion ≈ $34.81 Million |
-- |
About Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hy… Read more